Dr. Agarwal's Health Care Limited, a provider of eye care treatments and products, is gearing up for a market debut with an Initial Public Offering (IPO) worth ₹3,027.26 crores. This exciting investment opportunity opens to the public from January 29 to January 31, 2025, offering a mix of a fresh issue of 0.75 crore shares valued at ₹300 crores and an offer for sale of 6.78 crore shares worth ₹2,727.26 crores.
With a price band of ₹382 to ₹402 per share and a convenient lot size of 35 shares, this IPO offers an enticing entry point for investors. Retail investors can get in with a minimum investment of ₹14,070, making it an accessible opportunity to tap into the company’s promising growth trajectory. The share allotment will be finalized by February 3, 2025, with the shares expected to be listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) on February 5, 2025. Don’t miss out on this chance to be part of a rapidly expanding eye-care brand with a bright future ahead.
Dr. Agarwal's Health Care Limited IPO is a fundraise worth ₹3,027.26 crores comprising fresh issue of 0.75 crore shares and offer for sale of 6.78 crore shares. The IPO will be available for subscription from January 29, 2025, to January 31, 2025, providing an opportunity for investors looking to gain a stake in the eye care segment.
| Dr. Agarwal's Health Care IPO date | January 29, 2025 - January 31, 2025 |
| Price band | ₹382 to ₹402 per share |
| Face value | ₹1 per share |
| Lot size | 35 shares |
| Issue type | Book-built issue IPO |
| Fresh issue | 74,62,686 shares amounting to ₹300 crores |
| Offer for Sale (OFS) | 6,78,42,284 shares amounting to ₹2,727.26 crores |
| Total issue size | 7,53,04,970 shares amounting to ₹3,027.26 crores |
| Listing at | BSE, NSE |
| Share holding post issue | 31,58,79,846 shares |
| Share holding pre issue | 30,84,17,160 shares |
The Dr. Agarwal's Health Care Limited IPO opens for subscription on January 29, 2025, and closes on January 31, 2025, with allotment slated for February 3, 2025.
| IPO open date | January 29, 2025 (Wednesday) |
| IPO close date | January 31, 2025 (Friday) |
| Basis of allotment | February 3, 2025 (Monday) |
| Initiation of refunds | February 4, 2025 (Tuesday) |
| Credit of shares to demat account | February 4, 2025 (Tuesday) |
| Listing date on exchanges | February 5, 2025 (Wednesday) |
| Cut-off time for UPI mandate confirmation | 5 PM on January 31, 2025 (Friday) |
Dr. Agarwal's Health Care Limited, established in 2010, has emerged as a comprehensive eye care provider offering a wide spectrum of services from cataract and refractive surgeries to specialized treatments. With a robust network of 737 doctors across 193 facilities in 117 cities spanning 14 states and four union territories, the company has built a significant healthcare infrastructure dedicated to eye care.
In the six months leading to September 30, 2024, the company demonstrated remarkable performance, serving 1.15 million patients and conducting 140,787 surgeries. Their service portfolio includes advanced surgical interventions like small incision cataract surgery, robotic cataract procedures, LASIK, SMILE, corneal transplantation, and specialized treatments for glaucoma and other eye conditions, positioning them as a versatile and technologically advanced eye care solution provider.
Dr. Agarwal's Health Care Limited intends to strategically deploy its IPO proceeds towards two primary objectives: first, reducing its financial leverage by repaying or prepaying a portion of its existing borrowings, which will improve the company's balance sheet and financial flexibility; and second, allocating funds for general corporate purposes and potential unidentified inorganic acquisition opportunities, positioning the company to pursue strategic growth and expansion in the competitive healthcare services market.
The Dr. Agarwal's Health Care Limited IPO showcases a healthy market capitalization of ₹12,698.37 crores. Key performance indicators reflect the company's financial health, with a Return on Equity (RoE) of 9.33%, Return on Capital Employed (RoCE) of 14.61%, and the Return on Net Worth (RoNW) stands at 6.21%.
Meanwhile, the Price-to-Book Value (P/BV) is seen at 7.96 and the PAT Margin is 6.90. A comparison of earnings per share (EPS) reveals a pre-IPO EPS of ₹3.08 while it is ₹2.51 post-IPO. Similarly, the price to earnings ratio pre-IPO is 130.44 and it will be 160.48 post-IPO.
| Period Ended | September 30, 2024 | March 31, 2024 | March 31, 2023 | March 31, 2022 |
| Revenue | 837.94 | 1,376.45 | 1,031.49 | 713.78 |
| Assets | 3,393.41 | 2,752.82 | 1,825.17 | 1,026.13 |
| Profit After Tax | 39.56 | 95.05 | 103.23 | 43.16 |
| Net Worth | 1,502.67 | 1,337.68 | 627.83 | 212.34 |
| Reserves & Surplus | 1,509.11 | 1,365.86 | 652.63 | 236.27 |
| Total Borrowing | 373.68 | 387.79 | 356.18 | 290.18 |
Amount in ₹ crores
Dr. Agarwal's Health Care Limited is the largest eye care services provider in India, with a trusted brand and a comprehensive, end-to-end service offering. The company's scalable, asset-light hub-and-spoke operating model allows for efficient expansion while maintaining strong clinical excellence driven by a distinguished board and a history of surgical innovations. Its leadership team, composed of doctor-promoters and qualified medical professionals, is complemented by experienced management, ensuring continued growth and operational profitability. The booming healthcare market in India, particularly in eye care, provides a promising landscape for the company’s expansion, with projected industry growth driven by lifestyle changes, medical tourism, and rising incomes.
Additionally, Dr. Agarwal’s Health Care stands out for its commitment to technological advancements and patient-centric care. By investing in cutting-edge technology, it consistently improves treatment precision and sets new standards in eye care. Its diverse offerings in surgeries, optical products, and pharmaceuticals cater to a wide range of patient needs, positioning the company as a holistic healthcare ecosystem. With a strong brand presence and a wide network of hospitals, both domestically and internationally, the company is well-positioned for sustained growth in the eye care industry.
The company faces intense competition in the healthcare sector, where pricing pressures and the need for constant innovation can challenge profitability. Regulatory dependencies also present risks, as Dr. Agarwal’s Health Care must comply with stringent medical and financial regulations across various markets. Operating in multiple countries adds complexity, requiring substantial resources to navigate regulatory hurdles. Additionally, the company generates a significant portion of its revenue from surgeries, which could be negatively impacted by reduced patient footfall, reputational damage, doctor attrition, or changing medical practices.
Another key challenge is the reliance on skilled personnel, particularly doctors and medical staff. The company’s success hinges on recruiting and retaining top talent, and factors such as doctor turnover, competition for qualified professionals, and potential conflicts of interest could affect service quality, patient volumes, and overall performance. Furthermore, the company’s brand and reputation, crucial for maintaining trust and growth, could be compromised by service quality issues, technological adoption delays, medical malpractice, or negative publicity. These risks could impact its financial stability and long-term growth trajectory.
The Dr. Agarwal's Health Care Limited IPO presents a thrilling opportunity for investors to tap into the rapidly growing eye care sector at its early public stage. While the potential for early-stage growth is certainly enticing, making a well-informed investment decision is key. A careful evaluation of the company’s fundamentals, market position, and growth outlook will ensure that this exciting opportunity aligns with your financial goals and risk profile. Take the time to assess this investment thoroughly, and you may just unlock a promising addition to your portfolio. Ready to explore the possibilities? Do your research and make a strategic move today.
What is the Dr. Agarwal's Health Care IPO?
The Dr. Agarwal's Health Care Limited IPO is a main-board offering consisting of a fresh issue of 0.75 equity shares and an offer for sale of 6.78 crore shares with a face value of ₹1 per share, aiming to raise a total of ₹3,027.26 crores. The share price is set between ₹382 and ₹402, with a minimum order quantity of 35 shares. This IPO will be open for subscription from January 29, 2025, to January 31, 2025. Kfin Technologies Limited is the registrar while Kotak Mahindra Capital Company Limited, Morgan Stanley India Company Private Limited, Jefferies India Private Limited, Motilal Oswal Investment Advisors Limited are the book-running lead managers.
When will the Dr. Agarwal's Health Care IPO open?
The Dr. Agarwal's Health Care Limited IPO will open for subscription on January 29, 2025, and will close on January 31, 2025.
When is the Dr. Agarwal's Health Care IPO listing date?
The tentative listing date for the Dr. Agarwal's Health Care Limited IPO is Wednesday, February 5, 2025.
For android only